Synovial Sarcoma - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Synovial Sarcoma - Pipeline Review, H2 2015’, provides an overview of the Synovial Sarcoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Synovial Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Synovial Sarcoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Synovial Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Synovial Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Synovial Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Synovial Sarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Synovial Sarcoma - Overview 7
Pipeline Products for Synovial Sarcoma - Comparative Analysis 8
Synovial Sarcoma - Therapeutics under Development by Companies 9
Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 10
Synovial Sarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Synovial Sarcoma - Products under Development by Companies 14
Synovial Sarcoma - Products under Investigation by Universities/Institutes 15
Synovial Sarcoma - Companies Involved in Therapeutics Development 16
Adaptimmune Limited 16
EpiZyme, Inc. 17
Immune Design Corp. 18
Karyopharm Therapeutics, Inc. 19
Merck & Co., Inc. 20
Novartis AG 21
OncoTherapy Science, Inc. 22
Synovial Sarcoma - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
(ID-LV305 + ID-G305) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
everolimus - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
OTSA-101 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pembrolizumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
selinexor - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SSTC-104 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
tazemetostat - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Synovial Sarcoma - Recent Pipeline Updates 60
Synovial Sarcoma - Discontinued Products 90
Synovial Sarcoma - Product Development Milestones 91
Featured News & Press Releases 91
Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US 91
Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93
List Of Tables
Number of Products under Development for Synovial Sarcoma, H2 2015 7
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Comparative Analysis by Unknown Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Synovial Sarcoma - Pipeline by Adaptimmune Limited, H2 2015 16
Synovial Sarcoma - Pipeline by EpiZyme, Inc., H2 2015 17
Synovial Sarcoma - Pipeline by Immune Design Corp., H2 2015 18
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 19
Synovial Sarcoma - Pipeline by Merck & Co., Inc., H2 2015 20
Synovial Sarcoma - Pipeline by Novartis AG, H2 2015 21
Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2015 22
Assessment by Monotherapy Products, H2 2015 23
Assessment by Combination Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Synovial Sarcoma Therapeutics - Recent Pipeline Updates, H2 2015 60
Synovial Sarcoma - Discontinued Products, H2 2015 90
List Of Figures
Number of Products under Development for Synovial Sarcoma, H2 2015 7
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 23
Number of Products by Top 10 Targets, H2 2015 25
Number of Products by Stage and Top 10 Targets, H2 2015 25
Number of Products by Top 10 Mechanism of Actions, H2 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 27
Number of Products by Top 10 Routes of Administration, H2 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 29
Number of Products by Top 10 Molecule Types, H2 2015 31
Number of Products by Stage and Top 10 Molecule Types, H2 2015 31
